Cargando…
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materia...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047109/ https://www.ncbi.nlm.nih.gov/pubmed/31596130 http://dx.doi.org/10.1089/dia.2019.0286 |
_version_ | 1783502076468264960 |
---|---|
author | Sherr, Jennifer L. Buckingham, Bruce A. Forlenza, Gregory P. Galderisi, Alfonso Ekhlaspour, Laya Wadwa, R. Paul Carria, Lori Hsu, Liana Berget, Cari Peyser, Thomas A. Lee, Joon Bok O'Connor, Jason Dumais, Bonnie Huyett, Lauren M. Layne, Jennifer E. Ly, Trang T. |
author_facet | Sherr, Jennifer L. Buckingham, Bruce A. Forlenza, Gregory P. Galderisi, Alfonso Ekhlaspour, Laya Wadwa, R. Paul Carria, Lori Hsu, Liana Berget, Cari Peyser, Thomas A. Lee, Joon Bok O'Connor, Jason Dumais, Bonnie Huyett, Lauren M. Layne, Jennifer E. Ly, Trang T. |
author_sort | Sherr, Jennifer L. |
collection | PubMed |
description | Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materials and Methods: A 96-h hybrid closed-loop (HCL) study was conducted in a supervised hotel/rental home setting following a 7-day outpatient standard therapy (ST) phase. Eligible participants were aged 6–65 years with A1C <10.0% using insulin pump therapy or multiple daily injections. Meals during HCL were unrestricted, with boluses administered per usual routine. There was daily physical activity. The primary endpoints were percentage of time with sensor glucose <70 and ≥250 mg/dL. Results: Participants were 11 adults, 10 adolescents, and 15 children aged (mean ± standard deviation) 28.8 ± 7.9, 14.3 ± 1.3, and 9.9 ± 1.0 years, respectively. Percentage time ≥250 mg/dL during HCL was 4.5% ± 4.2%, 3.5% ± 5.0%, and 8.6% ± 8.8% per respective age group, a 1.6-, 3.4-, and 2.0-fold reduction compared to ST (P = 0.1, P = 0.02, and P = 0.03). Percentage time <70 mg/dL during HCL was 1.9% ± 1.3%, 2.5% ± 2.0%, and 2.2% ± 1.9%, a statistically significant decrease in adults when compared to ST (P = 0.005, P = 0.3, and P = 0.3). Percentage time 70–180 mg/dL increased during HCL compared to ST, reaching significance for adolescents and children: HCL 73.7% ± 7.5% vs. ST 68.0% ± 15.6% for adults (P = 0.08), HCL 79.0% ± 12.6% vs. ST 60.6% ± 13.4% for adolescents (P = 0.01), and HCL 69.2% ± 13.5% vs. ST 54.9% ± 12.9% for children (P = 0.003). Conclusions: The Omnipod personalized MPC algorithm was safe and performed well over 5 days and 4 nights of use by a cohort of participants ranging from youth aged ≥6 years to adults with T1D under supervised free-living conditions with challenges, including daily physical activity and unrestricted meals. |
format | Online Article Text |
id | pubmed-7047109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-70471092020-02-28 Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions Sherr, Jennifer L. Buckingham, Bruce A. Forlenza, Gregory P. Galderisi, Alfonso Ekhlaspour, Laya Wadwa, R. Paul Carria, Lori Hsu, Liana Berget, Cari Peyser, Thomas A. Lee, Joon Bok O'Connor, Jason Dumais, Bonnie Huyett, Lauren M. Layne, Jennifer E. Ly, Trang T. Diabetes Technol Ther Original Articles Background: The objective of this study was to assess the safety and performance of the Omnipod(®) personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an investigational device. Materials and Methods: A 96-h hybrid closed-loop (HCL) study was conducted in a supervised hotel/rental home setting following a 7-day outpatient standard therapy (ST) phase. Eligible participants were aged 6–65 years with A1C <10.0% using insulin pump therapy or multiple daily injections. Meals during HCL were unrestricted, with boluses administered per usual routine. There was daily physical activity. The primary endpoints were percentage of time with sensor glucose <70 and ≥250 mg/dL. Results: Participants were 11 adults, 10 adolescents, and 15 children aged (mean ± standard deviation) 28.8 ± 7.9, 14.3 ± 1.3, and 9.9 ± 1.0 years, respectively. Percentage time ≥250 mg/dL during HCL was 4.5% ± 4.2%, 3.5% ± 5.0%, and 8.6% ± 8.8% per respective age group, a 1.6-, 3.4-, and 2.0-fold reduction compared to ST (P = 0.1, P = 0.02, and P = 0.03). Percentage time <70 mg/dL during HCL was 1.9% ± 1.3%, 2.5% ± 2.0%, and 2.2% ± 1.9%, a statistically significant decrease in adults when compared to ST (P = 0.005, P = 0.3, and P = 0.3). Percentage time 70–180 mg/dL increased during HCL compared to ST, reaching significance for adolescents and children: HCL 73.7% ± 7.5% vs. ST 68.0% ± 15.6% for adults (P = 0.08), HCL 79.0% ± 12.6% vs. ST 60.6% ± 13.4% for adolescents (P = 0.01), and HCL 69.2% ± 13.5% vs. ST 54.9% ± 12.9% for children (P = 0.003). Conclusions: The Omnipod personalized MPC algorithm was safe and performed well over 5 days and 4 nights of use by a cohort of participants ranging from youth aged ≥6 years to adults with T1D under supervised free-living conditions with challenges, including daily physical activity and unrestricted meals. Mary Ann Liebert, Inc., publishers 2020-03-01 2020-02-21 /pmc/articles/PMC7047109/ /pubmed/31596130 http://dx.doi.org/10.1089/dia.2019.0286 Text en © Jennifer L. Sherr, et al., 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Original Articles Sherr, Jennifer L. Buckingham, Bruce A. Forlenza, Gregory P. Galderisi, Alfonso Ekhlaspour, Laya Wadwa, R. Paul Carria, Lori Hsu, Liana Berget, Cari Peyser, Thomas A. Lee, Joon Bok O'Connor, Jason Dumais, Bonnie Huyett, Lauren M. Layne, Jennifer E. Ly, Trang T. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title_full | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title_fullStr | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title_full_unstemmed | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title_short | Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions |
title_sort | safety and performance of the omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047109/ https://www.ncbi.nlm.nih.gov/pubmed/31596130 http://dx.doi.org/10.1089/dia.2019.0286 |
work_keys_str_mv | AT sherrjenniferl safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT buckinghambrucea safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT forlenzagregoryp safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT galderisialfonso safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT ekhlaspourlaya safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT wadwarpaul safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT carrialori safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT hsuliana safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT bergetcari safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT peyserthomasa safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT leejoonbok safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT oconnorjason safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT dumaisbonnie safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT huyettlaurenm safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT laynejennifere safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions AT lytrangt safetyandperformanceoftheomnipodhybridclosedloopsysteminadultsadolescentsandchildrenwithtype1diabetesover5daysunderfreelivingconditions |